TD Asset Management Inc Has $2.09 Million Stake in Bicara Therapeutics Inc. $BCAX

TD Asset Management Inc boosted its holdings in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) by 71.5% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 224,538 shares of the company’s stock after buying an additional 93,600 shares during the quarter. TD Asset Management Inc owned about 0.41% of Bicara Therapeutics worth $2,086,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the business. XTX Topco Ltd increased its position in Bicara Therapeutics by 4.1% during the first quarter. XTX Topco Ltd now owns 28,453 shares of the company’s stock worth $371,000 after buying an additional 1,119 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Bicara Therapeutics by 4.8% in the first quarter. Bank of New York Mellon Corp now owns 42,192 shares of the company’s stock valued at $550,000 after purchasing an additional 1,924 shares during the last quarter. CWM LLC acquired a new stake in shares of Bicara Therapeutics in the first quarter valued at about $29,000. Federated Hermes Inc. grew its position in shares of Bicara Therapeutics by 50.0% in the first quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $156,000 after purchasing an additional 4,000 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of Bicara Therapeutics in the first quarter valued at about $52,000.

Bicara Therapeutics Stock Up 4.9%

BCAX stock opened at $17.06 on Wednesday. Bicara Therapeutics Inc. has a twelve month low of $7.80 and a twelve month high of $28.09. The company has a market cap of $931.65 million and a PE ratio of -5.38. The business’s 50-day simple moving average is $13.53 and its 200 day simple moving average is $12.11.

Bicara Therapeutics (NASDAQ:BCAX) last released its earnings results on Tuesday, August 12th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.04. On average, equities research analysts anticipate that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a research report on Tuesday, October 14th. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price target on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. HC Wainwright lowered their price target on Bicara Therapeutics from $41.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, August 22nd. Finally, Piper Sandler assumed coverage on Bicara Therapeutics in a research report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $31.86.

Insider Buying and Selling

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $18.16, for a total transaction of $227,000.00. Following the sale, the chief operating officer directly owned 198,141 shares of the company’s stock, valued at approximately $3,598,240.56. The trade was a 5.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Ivan Hyep sold 6,415 shares of Bicara Therapeutics stock in a transaction that occurred on Thursday, October 9th. The shares were sold at an average price of $18.23, for a total value of $116,945.45. Following the sale, the chief financial officer directly owned 145,355 shares in the company, valued at $2,649,821.65. The trade was a 4.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 146,534 shares of company stock valued at $2,682,012 over the last ninety days.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.